reports
Number of Shares and Voting Rights of Innate Pharma as of December 31,...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of December 31, 2024: Total number of shares outstanding: 83,830,336 ordinary shares 6,494 Preferred Shares 2016 7,581 Preferred Shares...
Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 31 dé...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 31 décembre 2024 : Nombre d’actions composant le capital : 83 830 336 actions ordinaires 6 494 Actions de Préférence 2016 7 581 Actions de Préférence 2017 ...
Adaptimmune Therapeutics Plc: 5 directors
Five Directors at Adaptimmune Therapeutics Plc sold 133,839 shares at between 0.575USD and 0.582USD. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...
- Christophe-Raphaël Ganet
- Oliver Metzger
- Stephane Houri
TKA THYSSENKRUPP AG
ALESK ESKER SA
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
ADS ADIDAS AG
G1A GEA GROUP AG
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
TNG TRANSGENE SA
SZG SALZGITTER AG
LXS LANXESS AG
ASY ASSYSTEM SA
GXI GERRESHEIMER AG
KCO KLOECKNER & CO SE
VOE VOESTALPINE AG
BOSS HUGO BOSS AG
ACX ACERINOX SA
NOEJ NORMA GROUP SE
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
NDA AURUBIS AG
FTON FEINTOOL INTERNATIONAL HOLDING AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
EVK EVONIK INDUSTRIES AG
MCPHY MCPHY ENERGY SA
BNR BRENNTAG SE
JUN3 JUNGHEINRICH AG PREF
RIO RIO TINTO PLC
SIE SIEMENS AG
BHP BHP GROUP LTD
DUE DURR AG
JST JOST WERKE AG
ALCUR ARCURE SA
HAG HENSOLDT AG
FPE3 FUCHS PETROLUB SE
DTG DAIMLER TRUCK
R3NK RENK GROUP AG
QGEN QIAGEN N.V.
- Christophe-Raphaël Ganet
- Oliver Metzger
- Stephane Houri
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
ADS ADIDAS AG
G1A GEA GROUP AG
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
TNG TRANSGENE SA
SZG SALZGITTER AG
LXS LANXESS AG
ASY ASSYSTEM SA
GXI GERRESHEIMER AG
KCO KLOECKNER & CO SE
VOE VOESTALPINE AG
BOSS HUGO BOSS AG
ACX ACERINOX SA
NOEJ NORMA GROUP SE
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
NDA AURUBIS AG
FTON FEINTOOL INTERNATIONAL HOLDING AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
EVK EVONIK INDUSTRIES AG
MCPHY MCPHY ENERGY SA
BNR BRENNTAG SE
JUN3 JUNGHEINRICH AG PREF
RIO RIO TINTO PLC
SIE SIEMENS AG
BHP BHP GROUP LTD
DUE DURR AG
JST JOST WERKE AG
ALCUR ARCURE SA
HAG HENSOLDT AG
FPE3 FUCHS PETROLUB SE
DTG DAIMLER TRUCK
R3NK RENK GROUP AG
QGEN QIAGEN N.V.
- Martial Descoutures
- Oussema Denguir
Transgene : Share price under pressure for no apparent reason
The recent clinical results of TG4050 and BT-001 strengthen the group's ambitions for both personalized vaccines and oncolytic viruses. TG4050 becomes, in our opinion, its main compound, to which two other candidates could be added: BT-001 and TG6050 with phase I results expected in 2025. Despite these positive clinical results, we are significantly adjusting our TP from € 2.2 to € 1.4 to factor in mainly: 1/ the current account advance of the major shareholder TSGH (Institut Mérieux Group), and...
- Martial Descoutures
- Oussema Denguir
Transgene : Une pression sur le cours sans justification apparente
Les récents résultats cliniques de TG4050 et de BT-001 viennent renforcer les ambitions du groupe à la fois sur les vaccins individualisés et sur les virus oncolytiques. TG4050 devient, selon nous, son actif principal auquel pourraient se rajouter deux autres candidats : BT-001 et TG6050 dont les résultats de phase I sont attendus en 2025. Malgré ces résultats cliniques positifs, nous ajustons significativement notre OC de 2,2 € à 1,4 € pour intégrer essentiellement : 1/ l’avance en compte coura...
Transgene Announces Financial Calendar for 2025
Transgene Announces Financial Calendar for 2025 Strasbourg (France), January 14, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces its financial reporting dates for 2025: March 27, 2025: 2024 Fiscal Year Results April 24, 2025: First Quarter 2025 Financial Results May 15, 2025: Annual Shareholders' Meeting September 16, 2025: First Half 2025 Financial Results November 4, 2025: Third Quarter 2025 Financial Resul...
BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur...
BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur Geschäfts- und Pipeline-Entwicklung BioNTech fokussiert sich in der Umsetzung der Onkologie-Strategie auf tumorübergreifende (Pan-Tumor-) Therapieansätze basierend auf Kombinationen mit BNT327/PM8002 sowie den mRNA-Krebsimmuntherapie-KandidatenBioNTech will BNT327/PM8002 als innovativen immunonkologischen („IO“) Schlüsselkandidat für die Kombinationsstrategie des Unternehmens entwickeln, der auf ein breites Spektrum von Krebsindikationen abzieltFortschritte in der Entwicklung von BNT327/PM8002 mit dem Beginn der globalen...
EQS-News: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa ...
EQS-News: Heidelberg Pharma AG / Key word(s): Study Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma 13.01.2025 / 08:17 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma HDP-101 is well tolerated to date, with no signs of dose-limiting toxicities Complete remission observed in one patient from Cohort 5 Proprietary novel paylo...
EQS-News: Heidelberg Pharma startet Kohorte 7 der Phase I/IIa-Studie m...
EQS-News: Heidelberg Pharma AG / Schlagwort(e): Studie Heidelberg Pharma startet Kohorte 7 der Phase I/IIa-Studie mit dem BCMA-ATAC-Kandidaten HDP-101 zur Behandlung des Multiplen Myeloms 13.01.2025 / 08:17 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG Heidelberg Pharma startet Kohorte 7 der Phase I/IIa-Studie mit dem BCMA-ATAC-Kandidaten HDP-101 zur Behandlung des Multiplen Myeloms HDP-101 erweist sich bisher als gut verträglich und zeigt keine Anzeichen von dosislimitierenden Toxizitäten Vollständige Remission ...
- Brian Moretta
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: January 2025
Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
ARBB ARBUTHNOT BANKING GROUP
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
ACSO ACCESSO TECHNOLOGY GROUP
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
VTAS VOLTA FINANCE (GBP)
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
SNG SYNAIRGEN PLC
IPO IP GROUP
HAT H&T GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
A0MXLB NB PRIVATE EQUITY PARTNERS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
TISSUE REGENIX GROUP PLC
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan H...
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma indications – potential data readouts beginning with TEBE-AM in 2026 Enrolling Phase 1/2 trial with brenetafusp combinations in ovarian and lung cancer; ongoing dose escalation with IMC-R117C (PIWIL1) and IMC-P115C (PRAME-A02-HLE) Presenting initial HIV Phase 1 MAD data in the first quarter 2025 Progressing ...
Innate Pharma Announces Transformative Strategy to Accelerate Growth
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide. "Our updated strategy underscores Innate Pharma’s unwavering dedication to innovation, collaboration, and delivering transformative therapies for patients worldwide," said Jonathan Dickinson, Chief Executive Officer of Innate Phar...
Innate Pharma annonce une stratégie de transformation pour accélérer s...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui sa stratégie pour accélérer sa croissance. Ce plan global s'appuie sur trois piliers clés destinés à soutenir une croissance à long terme, à favoriser l'innovation et à apporter des solutions thérapeutiques transformatrices aux patients. « La mise à jour de notre stratégie souligne l'engagement immuable d'Innate Pharma en faveur de l'innovation, de la collaboration et de la mise à disposition de thérapies transformantes pour les pa...
- Martin Hall
Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
SNG SYNAIRGEN PLC
IPO IP GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
TXG 10X GENOMICS INC CLASS A
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
Z29 TISSUE REGENIX GROUP PLC
029 GROUP SE
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au ...
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 31 décembre 2024 Strasbourg, le 7 janvier 2025 – 18h00 Au titre du contrat de liquidité confié par Transgene à Natixis Oddo BHF SCA, à la date du 31 décembre 2024, les moyens suivants figuraient au compte de liquidité : 359 661 titres Transgene80 653,30 € Au cours du second semestre 2024, il a été négocié un total de : Achat 250 777 titres243 947,38 €1 154 transactionsVente229 905 titres230 275,17 €1 081 transactions Il est rappelé que lors de la mise en place du programme de liquidité en 2016, les moyens ...
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as o...
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024 Strasbourg, January 7, 2025 – 06:00 pm CET Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of December 31, 2024, the following resources were managed through the liquidity account: 359,661 shares€ 80,653.30 In the second half of 2024, a total of: Purchases 250,777 shares€ 243,947.381,154 market transactionsSales229 905 shares€ 230,275.171,081 market transactions It is recalled that when the liquidity program was initially established in 2016, the following resources...
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Confer...
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in in a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Californ...
Immunocore appoints Travis Coy, previously a Non-Executive Director, a...
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces tha...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.